This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Jan 2015

Catalent Pharma Solutions Further Expands its High Potency Handling

Catalent Pharma Solutions has announced the expansion of potent handling and manufacturing capabilities at its Somerset, NJ facility. Together with recently announced investments in high potency clinical packaging, as well as the acquisition of Micron Technologies, this investment further expands Catalent’s extensive suite of solutions for high potency compounds, from optimisation through clinical and commercial manufacturing of final dose form.



Catalent has completed the expansion of facility and engineering controls for its high potency tableting and OptiMelt Hot Melt Extrusion operations in Somerset to supplement existing potent capabilities in oral solid and Zydis Fast Dissolve manufacturing. The company is now investing in additional potent containment for large-scale blending, fluid bed processing, and high shear granulation, which will come online throughout the first half of 2015.



The expansion creates a manufacturing Center of Excellence for potent handling across Catalent’s portfolio of oral solid manufacturing solutions, which includes hot melt extrusion, high-shear and wet granulation processing, solvent-based capability, extrusion/spheronization, fluid-bed processing, Wurster coating, and compression and encapsulation.

 

The Somerset facility is capable of handling SafeBridge Category 3 and 4, with SafeBridge certification expected in July of 2015.



“With the growing pipeline for oncology and other highly potent compounds, industry demand for development and manufacture is increasing,” commented Jonathan Arnold, Vice President and General Manager of Catalent’s Advanced Delivery Technologies business. “Catalent has extensive experience in potent compound handling, now providing analytical, development, manufacturing and packaging services for over 300 Category 3 & 4 potency compounds across our global network. Our continued investment demonstrates our commitment to providing comprehensive solutions across the entire drug development cycle.”

Related News